PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer

Y. ZHANG, M. LIU, H. YANG, J. WANG, H. LIU, X. LI, J. LI, J. XU, X. LI

Abstract:

This study proposed to investigate the relationship of PIK3CA somatic mutations, the most commonactivating mutations in human breast cancer (BC), and the efficacy of neoadjuvant chemotherapy(NCT).Using a novel liquidchip technology, PIK3CA DNA somat ic mutations and HER2, PTEN,EGFR mRNA expression profiles were analyzed in formalin fixed paraffin embedded samples of 93.